Transition, Actinide, Or Lanthanide Metal Containing Patents (Class 424/9.42)
-
Patent number: 8309058Abstract: The invention concerns a transition metal coordination complex of general formula (I) {[M(X)]C(H2O)n}p wherein: M represents an element belonging to the lanthanide group; and L represents a decadentate chromophore ligand of general formula (II). R1, R2, R3 and R4 independently represent hydrogen or an alkyl or aryl radical. A1, A2, A3 and A4 independently represent a structure of general formula (III). U1, U2 and U3 independently represent C or N, and R5, R6 and R7 independently represent hydrogen, an alkyl or aryl radical. Y represents C, O, S, P or N, and m is an integer representing free valences of Y. R8 represents independently hydrogen, an alkyl or aryl radical. X represents a counter-ion, and n represents hydrating water molecules. p represents monomers. H2O represents the hydrating water molecules. The invention also concerns a method for preparing such a ligand by reaction between a 6-chloromethylpyridine-2-carboxylate ethyl ester and ethylenediamine in organic medium.Type: GrantFiled: September 12, 2006Date of Patent: November 13, 2012Assignee: Commissariat a l'Energie AtomiqueInventor: Marinella Mazzanti
-
Publication number: 20120282185Abstract: The invention provides a particle comprising a metal oxide which is doped with at least one rare earth element, wherein the metal oxide is selected from titanium dioxide, zinc oxide, cerium oxide and mixtures of two or more thereof. The invention also provides a pharmaceutical composition comprising the particles, and to uses of the particles and composition in the treatment and diagnosis of cancer.Type: ApplicationFiled: December 8, 2010Publication date: November 8, 2012Applicant: ISIS INNOVATION LIMITEDInventors: Peter James Dobson, Gareth Wakefield, Helen Elizabeth Townley
-
Publication number: 20120258051Abstract: A composition comprising a core comprising an iron oxide, a first shell comprising at least one plasmon active metal at least partially surrounding the core, a second shell comprising a dielectric material at least partially surrounding the first shell, and a third shell comprising at least one plasmon active metal at least partially surrounding the second shell.Type: ApplicationFiled: October 27, 2011Publication date: October 11, 2012Inventors: Charleson S. Bell, Shann Yu
-
Publication number: 20120177579Abstract: Compositions comprising a tripeptide having the sequence XC1C2; wherein X is any amino acid such that XC1C2 is capable of binding a metal in a square planar orientation or square pyramidal orientation or both; and wherein C1 and C2 are the same or different; and wherein C1 and C2 individually are chosen from a cysteine and a cysteine-like nonnatural amino acid, as well as metal-XC1C2 complexes and methods for forming such complexes.Type: ApplicationFiled: December 30, 2011Publication date: July 12, 2012Applicant: University of KansasInventors: Jennifer Ann Stowell Laurence, Anthony Andrew Vartia, Mary Elizabeth Krause
-
Publication number: 20120177580Abstract: Compositions comprising a tripeptide having the sequence XC1C2; wherein X is any amino acid such that XC1C2 is capable of binding a metal in a square planar orientation or square pyramidal orientation or both; and wherein C1 and C2 are the same or different; and wherein C1 and C2 individually are chosen from a cysteine and a cysteine-like nonnatural amino acid, as well as metal-XC1C2 complexes and methods for forming such complexes.Type: ApplicationFiled: March 23, 2012Publication date: July 12, 2012Applicant: University of KansasInventors: Jennifer Ann Stowell Laurence, Anthony Andrew Vartia, Mary Elizabeth Krause
-
Publication number: 20120156142Abstract: A diagnostic agent composition is provided which comprises a nanoparticle composition and a pharmaceutically acceptable carrier or excipient. The nanoparticle composition comprises a nanoparticulate metal oxide and a phosphorylated polyol, wherein the phosphorylated polyol comprises at least two phosphate groups and one or more hydrophilic groups selected from the group consisting of polyethylene ether moieties, polypropylene ether moieties, polybutylene ether moieties, and combinations of two or more of the foregoing hydrophilic moieties. The disclosure provides detailed guidance on methods of making and using such diagnostic agent compositions. The diagnostic agent compositions provided by the present invention are useful as contrast agents for medical diagnostic imaging techniques such as magnetic resonance (MR) imaging and X-ray imaging. The diagnostic agent composition may be administered to a subject via a variety of techniques, among them injection, inhalation, and ingestion.Type: ApplicationFiled: December 15, 2010Publication date: June 21, 2012Applicant: GENERAL ELECTRIC COMPANYInventors: Bruce Allan Hay, Brian Christopher Bales, Michael Todd Luttrell, Binil Itty Ipe Kandapallil
-
Publication number: 20120156132Abstract: It is an object of the present invention to provide a targeting agent that enables drug delivery to a neovascular site and the imaging of such a neovascular site, utilizing the effect of the agent to accumulate in the neovascular site. The present invention provides a targeting agent to a neovascular site, which comprises a gelatin-like protein.Type: ApplicationFiled: June 11, 2010Publication date: June 21, 2012Applicants: KYOTO UNIVERSITY, FUJIFILM CORPORATIONInventors: Kentaro Nakamura, Yasuhiko Tabata
-
Publication number: 20120148501Abstract: A solution comprising a defined concentration of purified tantalum clusters in a solvent selected from the group consisting of water, ethanol, ethylene glycol and propylene glycol; wherein said defined concentration is greater than 100 mM, preferably greater than 150 mM; most preferably greater than 300 mM. The purified tantalum clusters are obtained by sequentially washing crude tantalum clusters containing residual chloride ions with aqueous hydrochloric acid to remove residual sodium chloride; and washing the hydrochloric acid-washed tantalum clusters with diethyl ether to remove residual hydrochloric acid and water.Type: ApplicationFiled: December 8, 2010Publication date: June 14, 2012Inventors: Fred Geisler, Marc Schrier, Mihai Buretea
-
Publication number: 20120128583Abstract: The present invention relates to DTPA derivatives capable of forming complexes by combining with metals and the like, metal complexes formed by combining with the DTPA derivatives, MR and CT contrast agents including gold (Au) nano-particles of which surfaces are coated with the metal complexes, and a method for manufacturing the same. The MR and CT contrast agents according to the present invention have a high magnetic relaxation rate, thereby providing an excellent contrast enforcement effect and a long image acquisition time. Furthermore, the MR and CT contrast agents are not toxic to the human body, and are image contrast agents of dual molecules capable of being applied to both MR and CT.Type: ApplicationFiled: December 13, 2009Publication date: May 24, 2012Applicant: Kyungpook National University Industry Academic Cooperation FoundationInventors: Tae Jung Kim, Yong Min Jang, Ji Ae Park
-
Publication number: 20120087860Abstract: In another embodiment, a method for detecting and/or diagnosing a cancer in a subject is provided. The method may include administering an effective dose of a biotag to a subject, or alternatively, administering an effective dose of a targeted contrast to the subject, the targeted contrast comprising a contrast agent and a biotag as described herein for targeting a cancer biomarker. The method may further include exposing the subject to a diagnostic imaging technique; detecting a population of cells expressing the cancer biomarker; and quantifying the expression of the cancer biomarker in the population of cells, wherein an increased expression of the cancer biomarker indicates that the subject has cancer.Type: ApplicationFiled: May 24, 2011Publication date: April 12, 2012Inventors: Marek Malecki, Raf Malecki
-
Publication number: 20120087868Abstract: The invention provides nanoparticle-loaded cells and compositions useful for improved imaging and therapy, for example radio-therapy. The invention also provides methods of manufacture of nanoparticle-loaded cells, methods of administering the nanoparticle-loaded cells, and methods for treatment and/or imaging.Type: ApplicationFiled: October 6, 2011Publication date: April 12, 2012Inventors: Gabriele Todd, Alla Danilkovitch
-
Publication number: 20120052006Abstract: The present disclosure is directed generally to gold/lanthanide nanoparticle conjugates, such as gold/gadolinium nanoparticle conjugates, nanoparticle conjugates including polymers, nanoparticle conjugates conjugated to targeting agents and therapeutic agents, and their use in targeting, treating, and/or imaging disease states in a patient.Type: ApplicationFiled: February 17, 2010Publication date: March 1, 2012Applicant: COLORADO SCHOOL OF MINESInventors: Stephen G. Boyes, Misty D. Rowe
-
Publication number: 20120004531Abstract: A gold-coated iron oxide nanoparticle, method of making thereof, and method of using thereof is disclosed. The nanoparticle is substantially toxin free (making it clinically applicable), easily functionalized, and can serve as a contrast agent for a number of imaging techniques, including imaging a subject in at least two distinct imaging modes. Further, the nanoparticle is well-suited for therapeutic uses.Type: ApplicationFiled: March 16, 2010Publication date: January 5, 2012Inventors: Zdravka Medarova, Anna Moore, Mehment Yigit
-
Publication number: 20110311456Abstract: A marker alloy foreign implant made of a biodegradable metallic material and having the composition MgxYbyMz wherein x is equal to 10-60 atomic percent; y is equal to 40-90 atomic percent; z is equal to 0-10 atomic percent; M is one or more element selected from the group consisting of Ag, Zn, Au, Ga, Pd, Pt, Al, Sn, Ca, Nd, Ba, Si, and Ge; and wherein x, y, and z, together, and including contaminants caused by production, result in 100 atomic percent.Type: ApplicationFiled: June 20, 2011Publication date: December 22, 2011Applicant: BIOTRONIK VI PATENT AGInventors: Bruno Zberg, Bodo Gerold, Joerg Loeffler
-
Publication number: 20110264027Abstract: Tetrapyrollic photosensitizers and imaging agent compounds having A, B, C, and D rings and having a reduced B ring and an oxidized D ring. The compounds preferably have a purity of at least 95 percent and preferably have a fused system connected at an unsaturated carbon atom of the C ring nearest the D ring and at the unsaturated carbon atom between the C and D rings. The invention also includes a method of making the compounds at over 95 percent yield by starting with a B and D ring oxidized tetrapyrollic compound and dissolving it in a halogenated hydrocarbon solvent and treating it with sufficient nitroalkane solution of FeCl3.6H2O to oxidize the D ring and separating the resulting organic layer and drying.Type: ApplicationFiled: February 19, 2009Publication date: October 27, 2011Applicant: Health Research, Inc.Inventors: Ravindra K. Pandey, Chao Liu, Mahabeer Dobhal, William Potter, Janet Morgan, Allan Oseroff, Stephanie Pincus
-
Patent number: 8003409Abstract: The present invention measures defect fluorescence exhibited from a defect level mainly on a semiconductor nanoparticle surface site which has an energy level existing inside the forbidden band of energy levels inside the semiconductor nanoparticle.Type: GrantFiled: March 27, 2006Date of Patent: August 23, 2011Assignee: Hitachi Software Engineering Co., Ltd.Inventors: Keiichi Sato, Susumu Kuwabata
-
Publication number: 20110165075Abstract: The invention provides a family of agents that target integrins, which can be used as imaging agents and/or therapeutic agents. The agents can be used to image angiogenesis, inflammation or other physiological processes in a subject.Type: ApplicationFiled: March 13, 2009Publication date: July 7, 2011Inventors: Milind Rajopadhye, Guojie Ho, Bohumil Bednar, Le T. Duong, Paul J. Coleman
-
Publication number: 20110117027Abstract: The present invention teaches a micro-porous injectable, soft elastic, fully resorbable fibrin-based composition for use as a soft tissue lumen and void filler. The composition of the present application exhibits physical characteristics, such as mechanical properties, typically seen in elastomers and mechanical stability, which is superior to fibrin alone. A variety of properties of the composition of the present invention can be effectively fine-tuned and altered by adjusting type and content of the particles as well as of the plasticizer contained in the void filler composition.Type: ApplicationFiled: January 11, 2011Publication date: May 19, 2011Applicants: Baxter Healthcare S.A., Baxter International Inc.Inventors: John J. Barry, Andreas Goessl, Heinz Gulle, Monika Mangold, Melitta Bilban
-
Publication number: 20110104072Abstract: The present application discloses treating water insoluble nanoparticles, particularly nanoparticles of metals and metal compounds which find utility in diagnostic imaging such as MR and X-ray imaging, with an alpha-hydroxyphosphonic acid conjugate with a hydrophilic moiety to render the nanoparticles sufficiently hydrophilic to find utility in diagnostic imaging. Among the modified hydrophilic nanoparticles disclosed are those in which the hydrophilic moieties of the modifying conjugate are ethylene oxide based polymers and copolymers and zwitterions and the nanoparticles are composed of transition metal oxides such as superparamagnetic iron oxide and tantalum oxide. Disclosed are nanoparticles which are sufficiently hydrophilic to form stable aqueous colloidal suspensions. Also disclosed is diagnostic imaging such as MR and X-ray using the modified hydrophilic nanoparticles as contrast agents.Type: ApplicationFiled: October 30, 2009Publication date: May 5, 2011Applicant: GENERAL ELECTRIC COMPANYInventors: Brian Christopher Bales, Bruce Allan Hay, Binil Itty Ipe Kandapallil
-
Publication number: 20110097276Abstract: Methods for diagnosing prostate cancer, and differentiate prostate cancer from other prostate complications, and use of said method, and diagnosing and monitoring lymph gland metastasis, post operative examinations, and examinations during or after radiation, cytostatic, and androgen treatments are disclosed. The methods comprise injecting tracer-labelled PSA or hK2 specific antibodies, visualising PSA or hK2 producing tissue with the aid of a visualisation method, and diagnosing prostate cancer from the difference in visualisation.Type: ApplicationFiled: February 17, 2006Publication date: April 28, 2011Inventor: David Ulmert
-
Publication number: 20110064676Abstract: The present invention relates to diagnostic and therapeutic nanoparticles. More particularly, the present invention relates to creating a hybrid gold/gold sulfide nanoparticle with a chitosan matrix surrounding the metallic nanoparticle and a method for making the same. The chitosan-coated gold/gold sulfide nanoparticles can then be incorporated with additional therapeutic or diagnostic compounds such as iodine, antibodies, or other suitable compounds. The nanoparticles of the present invention have the dual capabilities of absorbing near infrared wavelength light to (1) act as a therapeutic agent by generating heat energy effective for cell ablation or for release of therapeutic compounds embedded in the chitosan matrix and (2) creating diagnostic benefit by incorporation of X-ray or MRI contrast-agents.Type: ApplicationFiled: September 14, 2010Publication date: March 17, 2011Inventors: Andre' M. Gobin, Guandong Zhang
-
Publication number: 20110044897Abstract: The invention relates to a method for targeting an imaging agent to cells of an animal to detect localized infections. More particularly, localized infections are detected by targeting imaging agents to inflammatory cells having receptors for a vitamin by using vitamin-imaging agent conjugates.Type: ApplicationFiled: May 23, 2008Publication date: February 24, 2011Inventors: Philip Stewart Low, Walter Anthony Henne, JR., Bindu Varghese, Ryan Rothenbuhler
-
Publication number: 20110020243Abstract: Disclosed are compositions comprising nanoparticles and uses thereof. Such nanoparticles include gold nanoparticles conjugated to glucose or a glucose derivative, which are useful as contrast agents in imaging methods such as computed tomography (CT). Nanoparticles disclosed herein are useful in imaging various cells, tissues, and organs, and are particularly useful in imaging tumors and tumor cells in vitro and in vivo.Type: ApplicationFiled: July 26, 2010Publication date: January 27, 2011Inventor: Bulent AYDOGAN
-
Publication number: 20100329991Abstract: The invention concerns a product consisting in an injection medicinal formulations comprising at least one compound to provide a viscous formulation, ethanol and at least one compound making said formulation opaque to X rays so as to control its delivery and its action. Said formulation is in particular useful for treating herniated invertebral discs but also in intervention having demonstrated the efficacy of pure ethanol: treatment of hepatocellular tumours or osteoid osteomas, renal cysts and arterial-veinous angiomas.Type: ApplicationFiled: August 27, 2010Publication date: December 30, 2010Inventors: Jacques Theron, Marc d'Aboville, Christine Marie Joseph D' Aboville, Soline Alix Marie D'Aboville, Côme Philippe Guy D'Aboville, Quentin Bruno Pierre D'Aboville, Grégoire Michel Séverin D'Aboville
-
Publication number: 20100310474Abstract: The present invention is directed to novel compositions and methods utilizing delivery agents comprising protein cages, medical imaging agents and therapeutic agents.Type: ApplicationFiled: April 1, 2010Publication date: December 9, 2010Applicant: MONTANA STATE UNIVERSITYInventors: Mark J. YOUNG, Trevor Douglas, Yves U. Idzerda
-
Publication number: 20100297019Abstract: The invention encompasses particles comprising metal atoms, methods of making the particles, and methods for using the particles. In particular, the particles may be used to image biological tissues or to deliver a bioactive agent.Type: ApplicationFiled: October 9, 2008Publication date: November 25, 2010Applicant: THE WASHINGTON UNIVERSITYInventors: Gregory M. Lanza, Samuel A. Wickline, Dipanjan Pan, Angana Senpan
-
Publication number: 20100284936Abstract: The present invention relates to liposomes comprising particles with cores of tungsten or tungsten in mixture with other metallic elements as the contrast enhancing material and to the use of such pharmaceuticals, specifically as contrast agents in diagnostic imaging and in particular in X-ray imaging of liver tumours.Type: ApplicationFiled: May 19, 2006Publication date: November 11, 2010Inventors: Oskar Axelsson, Kathrin Bjerknes
-
Publication number: 20100278749Abstract: Compositions of nanoparticles functionalized with at least one net positively charged group and at least one net negatively charged group, methods for making a plurality of nanoparticles, and methods of their use as diagnostic agents are provided. The nanoparticles have characteristics that result in minimal retention of the particles in the body compared to other nanoparticles. The nanoparticle comprises a core and a shell. The shell comprises a plurality of silane moieties; at least one silane moiety of the plurality is functionalized with a net positively charged group and at least one silane moiety of the plurality is functionalized with a net negatively charged group.Type: ApplicationFiled: April 29, 2009Publication date: November 4, 2010Applicant: GENERAL ELECTRIC COMPANYInventors: Peter John Bonitatibus, JR., Matthew David Butts, Robert Edgar Colborn, Amit Mohan Kulkarni, Bruce Allan Hay, Andrew Soliz Torres, Brian Christopher Bales, Michael Ernest Marino
-
Publication number: 20100266508Abstract: A kit for providing a contrast enhancer in a mammal for contrasting during imaging of the mammal comprises functionalized gold nanoparticles configured to be directed to one or more of a target organ, tissue and lesion of the mammal.Type: ApplicationFiled: June 27, 2008Publication date: October 21, 2010Applicant: THE CURATORS OF THE UNIVERSITY OF MISSOURIInventors: Vijaya Kattumuri, Kattesh V. Katti, Evan Boote, Raghuraman Kannan, Stan Casteel, Robert Churchill
-
Publication number: 20100254911Abstract: Multimodal nanoparticles are nanoparticles containing contrast agents for PAT and one or more of luminescence imaging, x-ray imaging, and/or MRI. The multimodal nanoparticles can have a dielectric core comprising an oxide with a metal coating on the core. The particles can be metal speckled. The multimodal nanoparticles can be used for therapeutic purposes such as ablation of tumors or by neutron capture in addition to use as contrast agents for imaging.Type: ApplicationFiled: August 28, 2008Publication date: October 7, 2010Applicant: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION INC.Inventors: Parvesh Sharma, Brij M. Moudgil, Glenn A. Walter, Stephen R. Grobmyer, Swadeshmukul Santra, Huabei Jiang, Scott Chang Brown, Edward W. Scott, Qizhi Zhang, Niclas Bengtsson
-
Publication number: 20100191096Abstract: The present invention relates to complexes comprising one or more marker(s) and one or more biomolecules. The complexes according to the present invention have a variety of utilities, such as utility as a contrast agent in imaging methods, for example magnetic resonance imaging.Type: ApplicationFiled: June 6, 2008Publication date: July 29, 2010Inventor: Olav Tenstad
-
Publication number: 20100166664Abstract: Compositions of nanoparticles functionalized with at least one zwitterionic moiety, methods for making a plurality of nanoparticles, and methods of their use as diagnostic agents are provided. The nanoparticles have characteristics that result in minimal retention of the particles in the body compared to other nanoparticles. The nanoparticle comprises a core, having a core surface essentially free of silica, and a shell attached to the core surface. The shell comprises at least one silane-functionalized zwitterionic moiety.Type: ApplicationFiled: December 29, 2008Publication date: July 1, 2010Applicant: GENERAL ELECTRIC COMPANYInventors: Matthew David Butts, Robert Edgar Colborn, Peter John Bonitatibus, JR., Amit Mohan Kulkarni, Bruce Allan Hay, Andrew Soliz Torres, Brian Christopher Bales, Michael Ernest Marino
-
Publication number: 20100166666Abstract: Compositions of nanoparticles functionalized with at least one zwitterionic moiety, methods for making a plurality of nanoparticles, and methods of their use as diagnostic agents are provided. The nanoparticles have characteristics that result in minimal retention of the particles in the body compared to other nanoparticles. The nanoparticle comprises a core, having a core surface essentially free of silica, and a shell attached to the core surface. The shell comprises at least one silane-functionalized zwitterionic moiety.Type: ApplicationFiled: December 29, 2008Publication date: July 1, 2010Applicant: GENERAL ELECTRIC COMPANYInventors: Matthew David Butts, Robert Edgar Colborn, Peter John Bonitatibus, JR., Amit Mohan Kulkarni, Bruce Allan Hay, Andrew Soliz Torres, Brian Christopher Bales, Michacl Ernest Marino
-
Publication number: 20100166665Abstract: Compositions of nanoparticles functionalized with at least one zwitterionic moiety, methods for making a plurality of nanoparticles, and methods of their use as diagnostic agents are provided. The nanoparticles have characteristics that result in minimal retention of the particles in the body compared to other nanoparticles. The nanoparticle comprises a core, having a core surface essentially free of silica, and a shell attached to the core surface. The shell comprises at least one silane-functionalized zwitterionic moiety.Type: ApplicationFiled: December 29, 2008Publication date: July 1, 2010Applicant: GENERAL ELECTRIC COMPANYInventors: Matthew David Butts, Robert Edgar Colborn, Peter John Bonitatibus, JR., Amit Mohan Kulkarni, Bruce Allan Hay, Andrew Soliz Torres, Brian Christopher Bales, Michael Ernest Marino
-
Patent number: 7744851Abstract: The present invention is directed to a method for preparing an anhydrous 18F-radiolabeled fluorinating agent by a nucleophilic reaction of a hydrated 18F-radiolabeled fluoride ion source with an unsaturated carrier compound; treating the 18F-radiolabeled carrier compound to produce a non-aqueous mixture of the 18F-radiolabeled carrier compound in a solvent; and reacting the 18F-radiolabeled carrier compound with a nucleophilic composition in a nucleophilic reaction to produce an anhydrous 18F-radiolabeled fluorinating agent. The present invention is also directed to an anhydrous 18F-radiolabeled fluorinating agent comprising the formula [QnM]x+(18F?)x. Additionally, the present invention is directed to an 18F-radiolabeled fluorinated radiopharmaceutical or an 18F-radiolabeled fluorinated radiotracer prepared by reacting the anhydrous 18F-radiolabeled fluorinating agent with a drug intermediate.Type: GrantFiled: July 16, 2007Date of Patent: June 29, 2010Assignee: Board Of Regents Of The University Of NebraskaInventors: Stephen Gregory DiMagno, Haoran Sun
-
Patent number: 7713517Abstract: Example compositions of liposomes with hydrophilic polymers on their surface, and containing relatively high concentrations of contrast-enhancing agents for computed tomography are provided. Example pharmaceutical compositions of such liposomes, when administered to a subject, provide for increased contrast of extended duration, as measured by computed tomography, in the bloodstream and other tissues of the subject. Also provided are example methods for making the liposomes containing high concentrations of contrast-enhancing agents, and example methods for using the compositions.Type: GrantFiled: April 21, 2004Date of Patent: May 11, 2010Assignee: Marval Biosciences, Inc.Inventors: Ananth Annapragada, Ravi V. Bellamkonda, Eric Hoffman, Chandra Vijayalakshmi
-
Publication number: 20100111859Abstract: A method for visualizing biological material, preferably by MRI, comprising the steps of: (i) bringing a population of coated nanoparticles into contact with said biological material, each of which nanoparticles comprises a) a metal oxide of a transition metal, said metal oxide preferably being paramagnetic and preferably comprising a lanthanide (+III) such as gadolinium (+III), and b) a coating covering the surface of the core particle, and (ii) recording the image; wherein the coating is hydrophilic and comprises a silane layer which is located next to the surface of the core particle and comprises one or more different silane groups which each comprises an organic group R and a silane-siloxane linkage where a) R comprises a hydrophilic organic group R? and a hydrophobic spacer B, b) O is oxygen directly binding to a surface metal ion of the metal oxide, and c) C is carbon and is also part of B.Type: ApplicationFiled: January 10, 2008Publication date: May 6, 2010Inventors: Oskar Axelsson, Kajsa Uvdal
-
Patent number: 7692002Abstract: The present invention relates to a metal complex of the general formula M(L)n, wherein each L is independently selected and represents a ligand and at least one L is vitamin B12 (cyanocobalamin) or a derivative thereof bound through the nitrogen atom of its cyanide group to M, which is an element selected from the transition metals, thus, forming a M-NC-[Co] moiety with [Co] representing vitamin B12 without cyanide and wherein n is 1, 2, 3, 4, 5 or 6. The complex can be prepared by mixing a precursor molecule with vitamin B12. The metal complexes can be used for radiodiagnostics, chemotherapy and radionuclide therapy.Type: GrantFiled: January 10, 2005Date of Patent: April 6, 2010Assignee: University of ZurichInventors: Roger Alberto, Susanne Barbara Kunze, Hector Knight Castro, Stefan Mundwiler
-
Publication number: 20100074848Abstract: Provided are an X-ray contrast agent using gold nanoparticles and a process for preparing the X-ray contrast agent. The X-ray contrast agent is prepared by capping gold nanoparticles with polyethylene glycol (PEG). The X-ray contrast agent is nontoxic and remains in a blood vessel for a long time so that the X-ray contrast agent can be usefully used as a computed tomography (CT) contrast agent for imaging blood vessels. Therefore, the X-ray contrast agent is useful for inspecting blood vessel structures and new blood vessels in a tumor, and obtaining perfusion images. In addition, gold provides better visibility than iodine when used in an X-ray contrast agent. Therefore, better x-ray images can be obtained using the X-ray contrast agent containing gold nanoparticles.Type: ApplicationFiled: August 31, 2006Publication date: March 25, 2010Inventor: Kwon-ha Yoon
-
Publication number: 20100047181Abstract: The following abstract will replace all prior versions of the abstract in the application: The mixture comprises a vanilloid receptor agonist with a substance, which inhibits nerve regeneration. The mixture is suitable for use, especially, as a painkiller.Type: ApplicationFiled: December 22, 2004Publication date: February 25, 2010Applicant: MESTEX AGInventor: Dominik Meyer
-
Publication number: 20090311179Abstract: The invention relates to a method of selectively targeting an active agent (or agent capable of becoming an active agent) to apoptotic cells in a vertebrate, comprising administering to said vertebrate a system comprising an arsenoxide (or arsenoxide equivalent) compound and said agent, wherein said system selectively targets apoptotic cells.Type: ApplicationFiled: April 30, 2009Publication date: December 17, 2009Applicant: NEW SOUTH INNOVATIONS PTY LIMITEDInventor: Philip John Hogg
-
Publication number: 20090263331Abstract: The present invention relates to nanoconjugates. In particular, the present invention provides nanoconjugates for diagnostic (e.g., imaging), research, and clinical (e.g., targeted treatment) applications.Type: ApplicationFiled: March 13, 2009Publication date: October 22, 2009Applicant: NORTHWESTERN UNIVERSITYInventors: Ai-Guo Wu, Tatjana Paunesku, Gayle E. Woloschak
-
Patent number: 7597876Abstract: The present application discloses compositions and methods of synthesis and use of F-18 labeled molecules of use, for example, in PET imaging techniques. In particular embodiments, the labeled molecules may be peptides or proteins, although other types of molecules including but not limited to aptamers, oligonucleotides and nucleic acids may be labeled and utilized for such imaging studies. In preferred embodiments, the F-18 label may be conjugated to a targeting molecule by formation of a metal complex and binding of the F-18-metal complex to a chelating moiety, such as DOTA, NOTA, DTPA, TETA or NETA. In other embodiments, the metal may first be conjugated to the chelating group and subsequently the F-18 bound to the metal. In other preferred embodiments, the F-18 labeled moiety may comprise a targetable conjugate that may be used in combination with a bispecific or multispecific antibody to target the F-18 to an antigen expressed on a cell or tissue associated with a disease, medical condition, or pathogen.Type: GrantFiled: December 19, 2007Date of Patent: October 6, 2009Assignee: Immunomedics, Inc.Inventors: William J. McBride, David M. Goldenberg
-
Publication number: 20090238756Abstract: Compositions and methods for imaging and for chemotherapy and radiotherapy are disclosed. More particularly, the invention concerns agents comprising a targeting moeity comprising a beta-adrenergic receptor targeting compound conjugated or embedded with ethylenediamine. The present invention also concerns methods of application of such agents for imaging and treatment of cardiovascular diseases, and kits for preparing a radiolabeled therapeutic or diagnostic agent.Type: ApplicationFiled: December 19, 2008Publication date: September 24, 2009Inventors: David J. Yang, Chang-Sok Oh, Saady Kohanim, Dong-Fang Yu, Richard Mendez, E. Edmund Kim
-
Publication number: 20090191121Abstract: Disclosed is the surprising discovery that aminophospholipids, such as phosphatidyserine and phosphatidylethanolamine, are specific, accessible and stable markers of the luminal surface of tumor blood vessels. The present invention thus provides aminophospholipid-targeted diagnostic and therapeutic constructs for use in tumor intervention. Antibody-therapeutic agent conjugates and constructs that bind to aminophospholipids are particularly provided, as are methods of specifically delivering therapeutic agents, including toxins and coagulants, to the stably-expressed aminophospholipids of tumor blood vessels, thereby inducing thrombosis, necrosis and tumor regression.Type: ApplicationFiled: February 13, 2009Publication date: July 30, 2009Inventors: Philip E. Thorpe, Sophia Ran, Rolf A. Brekken
-
Publication number: 20090110644Abstract: The invention provides nanoparticles consisting of a polymer which is a metal chelating agent coated with a magnetic metal oxide, wherein at least one active agent is covalently bound to the polymer, said nanoparticles may optionally further comprise at least one active agent physically or covalently bound to the outer surface of the magnetic metal oxide. Pharmaceutical compositions comprising these nanoparticles may be used, inter alia, for detection and treatment of tumors and inflammations.Type: ApplicationFiled: September 24, 2008Publication date: April 30, 2009Inventors: Shlomo Margel, Benny Perlstein, Chaya Brodie, Tom Mikkelsen
-
Publication number: 20090098047Abstract: The present invention is directed to bioconjugates of complexes represented by the formula: wherein R, R?, R1, R?1, R2, R?2, R3, R?3, R4, R?4, R5, R?5, R6, R?6, R7, R?7, R8, R?8, R9, R?9, M, X, Y, Z and n are defined herein for use as contrast agents in diagnostic imaging.Type: ApplicationFiled: August 4, 2008Publication date: April 16, 2009Applicants: Inotek Pharmaceuticals, Kereos, Inc.Inventors: William L. Neumann, Dennis P. Riley, Randy H. Weiss, Susan L. Henke, Patrick J. Lennon, Karl W. Aston
-
Publication number: 20090087383Abstract: The present invention is generally directed to core/shell nanoparticles, wherein such core/shell nanoparticles comprise a nanoparticle core and a nanoshell disposed about the nanoparticle core such that, in the aggregate, they form a core/shell nanoparticle that is operable for use as an imaging agent in X-ray/computed tomography (CT). Typically, such core/shell nanoparticle-based X-ray CT imaging agents further comprise a targeting species for targeting the imaging agent to diseased sites. Included herein are methods for forming such agents, comprising forming an ensemble of core/shell nanoparticles, wherein the mean diameter of the ensemble of core/shell nanoparticles is selected so as to render the nanoparticles in the ensemble substantially clearable by a mammalian kidney.Type: ApplicationFiled: November 24, 2008Publication date: April 2, 2009Applicant: GENERAL ELECTRIC COMPANYInventors: Peter John Bonitatibus, JR., David Cheney deMoulpied, Andrew Soliz Torres, Amit Mohan Kulkarni, Robert Edgar Colborn, Paul William Buckley
-
Publication number: 20090074674Abstract: The invention provides stabilized, biocompatible gold nanoparticles that are stabilized with material from polyphenols- or flavanoids-rich plant material or reactive phytochemical components of the plant material. The gold nanoparticles of the invention can be fabricated with an environmentally friendly method for making biocompatible stabilized gold nanoparticles. In methods of the invention, an aqueous solution containing gold salts is mixed with polyphenols- or flavanoids-rich plant material. In preferred embodiment methods of making, an aqueous solution containing gold salts is provided. The aqueous solution is mixed with black tea, turmeric, curcumin or cinnamon or a similar naturally occurring polyphenols- or flavanoids-rich plant material. The gold salts react to form biocompatible gold nanoparticles that are stabilized with a coating of the polyphenols- or flavanoids-rich plant material.Type: ApplicationFiled: September 17, 2008Publication date: March 19, 2009Inventors: Kattesh K. Katti, Raghuraman Kannan, Kavita K. Katti
-
Publication number: 20080241074Abstract: Cyclen-based chelates can be used as contrast agents for multi-modal imaging of tissue cells. The cyclen-based chelates are preferably polyazamacrocyclic molecules formed from 1,4,7,10 tetraazacyclododecane (“cyclen”) having varying chelating ions, phosphoester chains, and light harvesting moieties. By changing the chelating ion, phosphoester chain length and/or the light harvesting moiety different imaging techniques, such as MRI, CT, fluorescence and absorption, x-ray and NIR, may be employed to image the tissue cells. Additionally, the cyclen-based chelates may be conjugated to provide for site-specific delivery of the cyclen-based chelate to the desired tissue cells. The cyclen-based chelates may also be delivered to the tissue cells by attaching the cyclen-based to a polymeric delivery vehicle. Although these cyclen-based chelates have a wide variety of application, the preferred use is for imaging of cancer cells, such as brain cancer, for improving resection of a cancerous tissue.Type: ApplicationFiled: March 4, 2008Publication date: October 2, 2008Inventors: Darryl J. Bornhop, H. Charles Manning, Timothy Goebel